300363.SZ
博腾股份
SZSE · Healthcare · C 制造业 · CN
CNY 20.46
−6.53%Aug 22, 2026, 11:53 UTC
Porton Pharma Solutions terminated its Slovenia overseas project, leading to large asset impairments and write-offs that reduced net profit by over 350 million yuan.
Source:Aug 21, 2026, 10:58 UTC
Porton Pharma Solutions reported a net loss of 224 million yuan for the first half of 2026, swinging from a profit a year earlier.
Aug 3, 2026, 10:32 UTC
Porton Pharma Solutions' second-tier subsidiary Suzhou Porton Biopharmaceutical Co., Ltd. obtained a Drug Manufacturing License issued by the Jiangsu Provincial Drug Administration, valid until July 26, 2031, qualifying it to undertake commercial contract manufacturing of cell and gene therapy products.
Source:Jul 22, 2026, 10:42 UTC
Porton Pharma Solutions shareholder Tao Rong was placed on bail pending investigation by Zhongshan Public Security Bureau for accepting bribes by a non-state employee, effective from July 20, 2026.
Source:Jul 15, 2026, 12:18 UTC
Porton Pharma Solutions announced it will establish a wholly-owned subsidiary Chongqing Yaochu Biotechnology Co., Ltd. with a capital contribution of 30 million RMB in cash to explore the health consumer market.
Source:Jul 14, 2026, 09:49 UTC
Porton Pharma Solutions Ltd. terminated the construction of its R&D and production base project in Slovenia, resulting in asset impairment.
Source:Jul 14, 2026, 09:49 UTC
Porton Pharma Solutions Ltd. announced its expected net loss for the first half of 2026.
Source:Jul 3, 2026, 03:05 UTC
Porton Pharma Solutions successfully delivered a dual-payload ADC IND clinical sample through its one-stop protein and conjugate drug CDMO platform.
Source: